SYNCOMFSYNCOMF Forensic Risk Analysis

Pharmaceuticals
Risk ClassStable
Market CapN/A
Primary DriverGrowth Sustainability
Flagium AI Risk Score
Stable structural profile. Financial profile appears resilient.
5 / 100
+5 QoQ
Early Deterioration
Sentinel Insight

Financial profile remains stable for now. Weakness is detected in growth sustainability. No immediate concerns are visible. Risk is increasing at a faster pace.

6.1th %ile (Sector)Accel: +1 Qtrs
Updated2026-06-02
Market View
₹14.93▲1.08%
PeriodQ4 FY26

Score Waterfall
Absolute contribution points of each forensic pillar to the final risk score. Derived from: Sector Baseline + Active Penalties - Mitigation Buffers.

Growth Sustainability
+10.0 pts
Stability Adjustment
-5.0 pts
Final Composite Risk5 / 100

Investment Risk Thesis

Historical Trend

Current risk score has risen from 0 → 5 over 12 quarters.

Expected Direction
⚠ Watch
Primary Deterioration Drivers
  • Inventory Stress
  • Industrial Margin Stress
  • Working Capital Expansion
What to Watch Next Quarter
  • Inventory turnover
  • Operating cash flow
  • Operating profit margins

Active Risk Objects (4)

CriticalHigh
Inventory Stress
📊 Earnings QualityAnnualActive for 2 Years
More Detail
Impact Weight15/15
MomentumAccelerating
Last SignalQ4 FY2026
Inventory growth (52.1%) significantly outpaced revenue growth (-3.8%).

"Stock is piling up in the warehouse. Inventory turnover is slowing down dangerously."

Cash Conversion Deficit
📊 Earnings QualityAnnualActive for 2 Years
More Detail
Impact Weight6/15
MomentumAccelerating
Last SignalFY2026
SYNCOMF: OCF below Net Profit in 3/3 recent years.

"Cash conversion is dangerously low. Operational cash flow is significantly trailing reported PAT."

Industrial Margin Stress
📊 Earnings QualityAnnualActive for 1 Years
More Detail
Impact Weight12/15
MomentumDecaying
Last SignalQ4 FY2024
SYNCOMF: EBITDA margin compressed by 2.3 bps YoY and Raw material costs consumed an additional 11.1% of revenue YoY.

"Operating efficiency is stabilizing. The rate of margin deterioration has slowed."

Working Capital Expansion
💧 Liquidity & CoverageAnnualActive for 2 Years
More Detail
Impact Weight10/15
MomentumDecaying
Last SignalQ4 FY2024
Working capital expansion detected: Receivable days increased by 19.3%.

"Working capital pressure is receding. Cash previously locked in operations is being released."

Risk Trajectory
Historical 12-quarter risk trend (Q-11 to Q0) followed by a 2-quarter predictive funnel (Q+1, Q+2).
Loading Chart
Resilience Matrix
Diagnostic benchmarking comparing structural sensitivity and risk buffers against sector medians.
MetricValuevs SectorSignal
Volatility (σ)4.097.70✅ RESILIENT
Sensitivity (ε_s)11.00✅ RESILIENT
Escalation Prob.5%5%✅ NEUTRAL
Safety Buffer+61.0+47.0✅ RESILIENT
Forensic Benchmark Context: Pharmaceuticals (n=99 peers)

Correlation Analysis
Visualizing the relationship between stock price movement and structural risk objects.

Loading Chart
Share Price
Risk Score (0-100)
Market Performance
₹14.93(+1.08%)
1M Divergence+6.39%
1 Week-6.69%
1 Month+8.66%
6 Months-2.48%
1 Year-31.58%
2 Year+24.94%
3 Year+121.19%
Sector Average (1M)+2.27%
Sentinel Forensic Assessment
ALGORITHMIC RISK PROFILE • NON-ADVISORY

The structural architecture is currently robust. Capital resilience buffers in growth sustainability remain well-maintained against forensic benchmarks. Systematic scans of core structural metrics confirm the absence of material structural stress. Strategic vigilance is advised as structural decay is accelerating.

SYNCOMF • MARKET STRUCTURE

Stage 1 — Accumulation

The company is in a foundational phase. Risk metrics are stabilizing as the company builds a base for potential future fundamental improvement.

Stage Transition Prob.9%
Trend QualityEarly Base
Phase Progression
Phase Progression Score40%
Readiness LabelLow (Early Base Consolidation)
Probability of Advancing9%
CoinTree Momentum
Composite Z-Score+0.3164σ
Improving momentum strength
Universe Rank
A cross-sectional rank of this stock's composite momentum score compared to all other tracked equities in the universe. A rank of #1 of 1035 means it has the strongest overall price momentum in the market.
#586 of 2716
Top 21.58% in momentum strength
Timeframe Sparklines
1W-6.7%
1M+8.7%
6M-2.5%
Weinstein Indicators
150 DMA₹13.99
200 DMA₹14.78
150 DMA Slope-1.9945%Declining
Relative Strength+3.01%Leading
Relative Turnover (RTR)1.8643
ParticipationHealthy

PEER COMPARISON

Ranked comparison against sector peers

This company appears relatively stable compared to the Sector Mean (19).
ABBOTINDIAABBOTINDIA
0 Risk
Sector %ile0th
Delta0
Active Flags0
Accel+0
Governance

Stable

SYNCOMFSYNCOMF
5 Risk
Sector %ile6th
Delta+5
Active Flags4
Accel+1
Growth Sustainability

Stable

AARTIDRUGSAarti Drugs Limited
19 Risk
Sector %ile51th
Delta-5
Active Flags11
Accel+0
Competitive Position

Stable

AAREYDRUGSAarey Drugs & Pharmaceuticals Limited
23 Risk
Sector %ile63th
Delta-5
Active Flags20
Accel+0
Balance Sheet Stress

Watch

* Peer comparison is based on risk signals, not valuation or returns.

Risk Profiles

Solvency
10100th %ile
VS Sector Median (8.5)
Governance
10100th %ile
VS Sector Median (8.5)
Earnings Quality
10100th %ile
VS Sector Median (8.5)
Balance Sheet Stress
10100th %ile
VS Sector Median (8.5)
Competitive Position
10100th %ile
VS Sector Median (8.5)
Growth Sustainability
00th %ile
VS Sector Median (8.5)

Deterioration Timeline

2026

Inventory Stress

2026

Cash Conversion Deficit

2025

Inventory Stress

2025

Cash Conversion Deficit

2024

Working Capital Expansion

2024

Industrial Margin Stress

2024

Working Capital Expansion

Key Financials (INR Cr)

PeriodRevenueNet ProfitOCFDebt
FY202652176581
FY202548249235
FY202427725-672
FY2023239201183